Irrus Investments

FeelTect is a medical device company based in Galway, Ireland, founded in 2019. The company specializes in developing and marketing a connected-health technology known as Tight Alright, which is designed to measure and monitor sub-bandage pressure during compression therapy for venous leg ulcers (VLUs). This technology addresses a critical challenge in VLU treatment, as improper pressure application can lead to ineffective or dangerous outcomes. By providing live readings and recorded data, FeelTect's device allows both patients and healthcare providers to ensure that compression therapy is applied safely and effectively, ultimately facilitating optimal, individualized treatment regimens. The innovation not only enhances patient care but also aims to reduce the economic burden associated with VLU management.

Bluedrop Medical Limited specializes in developing, manufacturing, and commercializing an Internet of Things-enabled device designed for the early detection of diabetic foot ulcers. Founded in 2014 and based in Galway, Ireland, the company offers a home-based system that conducts daily scans of patients' feet. This data is then transmitted to the cloud for analysis using advanced algorithms capable of identifying abnormalities. By detecting skin damage early, the device aims to significantly reduce the risk of amputation, which is a critical concern as up to 25% of individuals with diabetes may develop foot ulcers, often due to peripheral neuropathy. The innovative technology not only enhances patient care but also has the potential to lower healthcare costs associated with severe complications arising from untreated foot ulcers.

Hooke Bio Ltd., established in 2014 and located in Shannon, Ireland, specializes in developing microfluidic-based technologies for drug screening and related applications. The company has created a fully integrated high throughput screening system that focuses on 3D microtissues, including spheroids, organoids, and mini-organs. Its patented Mera technology generates biological data from these microtissues, aiming to minimize the use of animal models in preclinical studies and expedite drug development processes. Hooke Bio’s innovations facilitate the creation of more accurate disease models for testing new drugs and enable the testing of existing therapies using patient-specific disease samples, ultimately enhancing the ability of medical professionals to treat patients effectively.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Bluedrop Medical Limited specializes in developing, manufacturing, and commercializing an Internet of Things-enabled device designed for the early detection of diabetic foot ulcers. Founded in 2014 and based in Galway, Ireland, the company offers a home-based system that conducts daily scans of patients' feet. This data is then transmitted to the cloud for analysis using advanced algorithms capable of identifying abnormalities. By detecting skin damage early, the device aims to significantly reduce the risk of amputation, which is a critical concern as up to 25% of individuals with diabetes may develop foot ulcers, often due to peripheral neuropathy. The innovative technology not only enhances patient care but also has the potential to lower healthcare costs associated with severe complications arising from untreated foot ulcers.

Using the latest in-house technology Allview Healthcare gives you access to leading Consultant and surgical services Rapid diagnosis and care. Currently the largest dermatology provider across Ireland, servicing both the HSE (State Health Provider) and the VHI (Ireland's largest private insurance company) A highly experienced management team and board of directors with both medical and technical professionals whose main aim is to ensure that patients receive the best care by the best consultant at the right time. We work hard to ensure our best practice, clinical governance and quality assurance is at its highest level thus leading to extremely high patient satisfaction.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

OncoMark Limited, founded in 2007 and based in Dublin, Ireland, specializes in the discovery and development of diagnostic tools and therapeutic targets for cancer patients. The company focuses on companion diagnostic tests that assist pharmaceutical firms in selecting patients who are most likely to benefit from specific cancer treatments, thereby optimizing the drug development process and improving clinical trial outcomes. OncoMark's product offerings include tissue-based biomarker assays for pharmacodynamic and patient stratification studies, as well as a Biomarker Interpretation Workflow platform that automates various analytical processes. The company is developing a portfolio of diagnostic tests for key cancer types, including breast, colorectal, prostate, and melanoma, supported by substantial EU R&D funding. With a small team and a strong advisory board, OncoMark aims to enhance patient care by providing tools that facilitate more effective treatment decisions based on genetic markers and other biomarkers.

Adama Innovations Ltd. is a company based in Dublin, Ireland, that specializes in developing nanotechnology solutions for advanced manufacturing. Founded in 2010 as a spin-out from CRANN, the nanotechnology institute at Trinity College Dublin, the company focuses on creating high-resolution patterns on ultra-hard materials. Its flagship product is a diamond-based nano-scale probe designed for atomic force microscopy (AFM), which allows for precise imaging, measurement, and manipulation at the nanoscale. These probes have diverse applications, including general topography, electrical analysis, and sidewall characterization. Additionally, Adama Innovations produces diamond sharp cones and flare-shaped probes for various metrology applications. The company’s technology also supports the manufacturing of medical devices by enhancing the capabilities of injection molds and forming dies, while contributing to labeling and anti-counterfeiting solutions.

Embo Medical is based in National University of Ireland. Embo is developing the first true one-shot (one device per vessel) vascular embolisation device. The product is aimed at the peripheral vascular embolization market, a market where physicians perform about 180,000 procedures per year worldwide.